Lumos Pharma Inc
NASDAQ:LUMO

Watchlist Manager
Lumos Pharma Inc Logo
Lumos Pharma Inc
NASDAQ:LUMO
Watchlist
Price: 4.34 USD Market Closed
Market Cap: 37.5m USD

Operating Margin
Lumos Pharma Inc

-1 647.6%
Current
-3 727%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 647.6%
=
Operating Profit
-36.3m
/
Revenue
2.2m

Operating Margin Across Competitors

No Stocks Found

Lumos Pharma Inc
Glance View

Market Cap
37.5m USD
Industry
Biotechnology

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2011-11-11. The firm is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

LUMO Intrinsic Value
10.94 USD
Undervaluation 60%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 647.6%
=
Operating Profit
-36.3m
/
Revenue
2.2m
What is the Operating Margin of Lumos Pharma Inc?

Based on Lumos Pharma Inc's most recent financial statements, the company has Operating Margin of -1 647.6%.

Back to Top